Q2 2025 · 13F-HR
Patient Square Capital LPholdings as filed
Filed 2025-08-11 · accession 0000950123-25-007478
$277.4M
Reported value
19
Positions
2025-06-30
Period end
The Brief · Patient Square Capital LP · Q2 2025
AI · grounded in 13F
Patient Square Capital LP established a new position in ROIV valued at $140.6M. The fund also added new stakes in INSM for $36.1M and ARGX for $16M. Other new entries include EYPT, LQDA, and OCUL. The fund ended the period with 19 positions and total AUM of $277.4M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G76279101 | ROIV | ROIVANT SCIENCES LTD. | $140.6M | 50.7% | 12,480,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $36.1M | 13.0% | 358,800 | Common | SOLE |
| 04016X101 | ARGX | ARGENX SE - ADR | $16.0M | 5.76% | 29,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS, INC. | $12.7M | 4.59% | 1,352,837 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $12.7M | 4.58% | 1,020,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX, INC. | $7.6M | 2.74% | 817,699 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS, INC. | $6.5M | 2.36% | 868,897 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS, INC. | $6.1M | 2.20% | 140,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS, INC. | $5.8M | 2.08% | 113,462 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORPORATION | $5.5M | 1.97% | 154,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS, INC. | $4.9M | 1.78% | 245,838 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS, INC. | $4.7M | 1.69% | 412,296 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS, INC. | $4.6M | 1.68% | 139,732 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N. V. | $4.3M | 1.55% | 244,283 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE, INC. | $3.9M | 1.41% | 74,000 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS, INC. | $3.0M | 1.07% | 2,635,000 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $1.0M | 0.36% | 716,000 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $730,650 | 0.26% | 15,000 | Common | SOLE |
| 92941V308 | VYNE | VYNE THERAPEUTICS INC. | $523,104 | 0.19% | 317,033 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.